Click through the PLOS taxonomy to find articles in your field.
For more information about PLOS Subject Areas, click
here.
Loading metrics
Open Access
Correction
Correction: Raltegravir Non-Inferior to Nucleoside Based Regimens in SECOND-LINE Therapy with Lopinavir/Ritonavir over 96 Weeks: A Randomised Open Label Study for the Treatment Of HIV-1 Infection
Janaki Amin,
Mark A. Boyd,
Nagalingeswaran Kumarasamy,
Cecilia L. Moore,
Marcello H. Losso,
Chidi A. Nwizu,
Lerato Mohapi,
Stephen J. Kerr,
Annette H. Sohn,
Hedy Teppler,
Boris Renjifo,
Jean-Michel Molina,
Sean Emery,
David A. Cooper,
SECOND-LINE
Correction: Raltegravir Non-Inferior to Nucleoside Based Regimens in SECOND-LINE Therapy with Lopinavir/Ritonavir over 96 Weeks: A Randomised Open Label Study for the Treatment Of HIV-1 Infection